BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24912180)

  • 1. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.
    Tamzalit F; Barbieux I; Plet A; Heim J; Nedellec S; Morisseau S; Jacques Y; Mortier E
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8565-70. PubMed ID: 24912180
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Anton OM; Peterson ME; Hollander MJ; Dorward DW; Arora G; Traba J; Rajagopalan S; Snapp EL; Garcia KC; Waldmann TA; Long EO
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):522-531. PubMed ID: 31871169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
    Chenoweth MJ; Mian MF; Barra NG; Alain T; Sonenberg N; Bramson J; Lichty BD; Richards CD; Ma A; Ashkar AA
    J Immunol; 2012 May; 188(9):4149-57. PubMed ID: 22447977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different NK cell developmental events require different levels of IL-15 trans-presentation.
    Lee GA; Liou YH; Wang SW; Ko KL; Jiang ST; Liao NS
    J Immunol; 2011 Aug; 187(3):1212-21. PubMed ID: 21715685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.
    Mortier E; Woo T; Advincula R; Gozalo S; Ma A
    J Exp Med; 2008 May; 205(5):1213-25. PubMed ID: 18458113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.
    Elpek KG; Rubinstein MP; Bellemare-Pelletier A; Goldrath AW; Turley SJ
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21647-52. PubMed ID: 21098276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
    Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
    Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
    Rowley J; Monie A; Hung CF; Wu TC
    J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.
    Wu Z; Xue HH; Bernard J; Zeng R; Issakov D; Bollenbacher-Reilley J; Belyakov IM; Oh S; Berzofsky JA; Leonard WJ
    Blood; 2008 Dec; 112(12):4411-9. PubMed ID: 18796634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
    Votavova P; Tomala J; Kovar M
    Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.
    Chertova E; Bergamaschi C; Chertov O; Sowder R; Bear J; Roser JD; Beach RK; Lifson JD; Felber BK; Pavlakis GN
    J Biol Chem; 2013 Jun; 288(25):18093-103. PubMed ID: 23649624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
    Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
    J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation.
    Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O
    J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
    Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
    Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions.
    Ullrich E; Bonmort M; Mignot G; Jacobs B; Bosisio D; Sozzani S; Jalil A; Louache F; Bulanova E; Geissman F; Ryffel B; Chaput N; Bulfone-Paus S; Zitvogel L
    J Immunol; 2008 Jun; 180(12):7887-97. PubMed ID: 18523252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
    Burkett PR; Koka R; Chien M; Chai S; Boone DL; Ma A
    J Exp Med; 2004 Oct; 200(7):825-34. PubMed ID: 15452177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
    Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
    Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
    Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
    J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.